Plain-English translation of NCT05983250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called levosimendag in people who have high blood pressure in their lungs combined with a specific type of heart failure. Researchers want to see if this medication helps people exercise more easily and reduces their symptoms. About 230 patients will receive either the medication or a placebo (a pill with no active ingredient) for 12 weeks.
Many people struggle with a combination of high lung pressure and heart failure but have limited treatment options available. This medication might offer a new way to help these patients feel less tired during daily activities and improve their quality of life.
If you join this study, you'll first have a screening period of up to 30 days to confirm you're eligible through various heart tests. You'll then be randomly assigned to take either the study medication or a placebo by mouth every day for 12 weeks. During those 12 weeks, you'll have regular visits to check how you're doing, and you may have the option to continue in an extended phase lasting nearly 2 years after the main study ends.
AI-generated summary from trial data · Aug 10, 2026 · Not medical advice
United States